Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Equity Ratio (2016 - 2025)

Cardiff Oncology's Equity Ratio history spans 15 years, with the latest figure at 0.73 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 14.06% year-over-year to 0.73; the TTM value through Dec 2025 reached 0.73, down 14.06%, while the annual FY2025 figure was 0.73, 14.06% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.73 at Cardiff Oncology, down from 0.76 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.97 in Q2 2021 and bottomed at 0.73 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.88 (2023), against an average of 0.87.
  • The largest annual shift saw Equity Ratio skyrocketed 85.34% in 2021 before it decreased 14.06% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.94 in 2021, then dropped by 2.53% to 0.92 in 2022, then decreased by 6.66% to 0.85 in 2023, then dropped by 0.09% to 0.85 in 2024, then fell by 14.06% to 0.73 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Equity Ratio are 0.73 (Q4 2025), 0.76 (Q3 2025), and 0.77 (Q2 2025).